Takeda Sues Amneal Over Gout Drug Generic

Law360, New York (October 22, 2013, 4:55 PM EDT) -- Takeda Pharmaceuticals USA Inc. accused generic-drug manufacturer Amneal Pharmaceuticals LLC of infringing its patents for a gout medication in Delaware federal court Monday, adding to Takeda's growing legal battles over the drug.

New Jersey-based Amneal Pharmaceuticals has infringed five of Takeda’s patents for Colcyrs, an oral medication whose active ingredient, colchicine, is designed to reduce the pain of gout attacks and to treat a rare disease known as familial Mediterranean fever, according to the complaint. The action stems from Amneal’s renewed efforts to bring a generic...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.